Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast

February 25, 2020 GMT

BRISBANE, Calif.--(BUSINESS WIRE)--Feb 25, 2020--

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2019 financial results before market opens on Friday, February 28, 2020. The press release will be followed by a conference call at 8:00 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 4609858. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 4609858.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200225006049/en/

CONTACT: Investor Relations – Global

McDavid Stilwell

510-970-6000, x219

mstilwell@sangamo.com Media Inquiries – Global

Aron Feingold

510-970-6000, x421

afeingold@sangamo.com Investor Relations and Media Inquiries – European Union & United Kingdom

Caroline Courme

33 4 97 21 27 27




SOURCE: Sangamo Therapeutics, Inc.

Copyright Business Wire 2020.

PUB: 02/25/2020 04:30 PM/DISC: 02/25/2020 04:30 PM